PDF(Pubmed)
Abstract：
BACKGROUND: Heart failure is a clinical condition with high mortality and morbidity that occurs when the heart is unable to pump enough blood to meet the metabolic demands of the body. The pharmacological management of heart failure has been revolutionized over the past decade with novel treatments.
OBJECTIVE: The aim of the review is to highlight the recent pharmacological advances in the management of heart failure.
RESULTS: Sodium-glucose cotransporter-2 inhibitor (SGLT2i), iron carboxymaltose, finerenone, omecamtiv mecarbil, and vericiguat have been shown to reduce hospitalization for heart failure. However, only SGLT2i, vericiguat, and omecamtiv mecarbil have been shown to reduce cardiovascular death. Finerenone has been shown to reduce cardiovascular events and renal adverse outcomes in patients with diabetes and kidney disease. Currently, only SGLT2i has been studied in patients beyond the heart failure with reduced ejection fraction population.
CONCLUSIONS: The current quadruple therapy in the treatment of heart failure has demonstrated a reduction in the hospitalization of patients and a decrease in mortality associated with the condition. Individualized heart failure therapy research have shown some benefit in select heart failure patients. Further research on novel therapies will help improve heart failure patient outcomes.
OBJECTIVE: The aim of the review is to highlight the recent pharmacological advances in the management of heart failure.
RESULTS: Sodium-glucose cotransporter-2 inhibitor (SGLT2i), iron carboxymaltose, finerenone, omecamtiv mecarbil, and vericiguat have been shown to reduce hospitalization for heart failure. However, only SGLT2i, vericiguat, and omecamtiv mecarbil have been shown to reduce cardiovascular death. Finerenone has been shown to reduce cardiovascular events and renal adverse outcomes in patients with diabetes and kidney disease. Currently, only SGLT2i has been studied in patients beyond the heart failure with reduced ejection fraction population.
CONCLUSIONS: The current quadruple therapy in the treatment of heart failure has demonstrated a reduction in the hospitalization of patients and a decrease in mortality associated with the condition. Individualized heart failure therapy research have shown some benefit in select heart failure patients. Further research on novel therapies will help improve heart failure patient outcomes.
摘要：
背景：心力衰竭是一种具有高死亡率和高发病率的临床疾病，发生在心脏无法泵送足够的血液以满足身体的代谢需求时。在过去的十年中，通过新颖的治疗方法，心力衰竭的药理管理发生了革命性的变化。
目的：本综述旨在强调治疗心力衰竭的药物研究进展。
结果：钠-葡萄糖协同转运蛋白-2抑制剂（SGLT2i），铁羧基麦芽糖，Finerenone,omecamtivmecarbil,和Vericiguat已被证明可以减少心力衰竭的住院时间。然而,只有SGLT2i，Vericiguat,和omecamtivmecarbil已被证明可以减少心血管死亡。在患有糖尿病和肾脏疾病的患者中，已经证明了Finerenone可以减少心血管事件和肾脏不良结局。目前,仅SGLT2i在射血分数降低的心力衰竭人群以外的患者中进行了研究.
结论：目前治疗心力衰竭的四联疗法已证明可减少患者的住院时间，并降低与该病相关的死亡率。个性化的心力衰竭治疗研究已经显示出在选择心力衰竭患者中的一些益处。对新疗法的进一步研究将有助于改善心力衰竭患者的预后。
目的：本综述旨在强调治疗心力衰竭的药物研究进展。
结果：钠-葡萄糖协同转运蛋白-2抑制剂（SGLT2i），铁羧基麦芽糖，Finerenone,omecamtivmecarbil,和Vericiguat已被证明可以减少心力衰竭的住院时间。然而,只有SGLT2i，Vericiguat,和omecamtivmecarbil已被证明可以减少心血管死亡。在患有糖尿病和肾脏疾病的患者中，已经证明了Finerenone可以减少心血管事件和肾脏不良结局。目前,仅SGLT2i在射血分数降低的心力衰竭人群以外的患者中进行了研究.
结论：目前治疗心力衰竭的四联疗法已证明可减少患者的住院时间，并降低与该病相关的死亡率。个性化的心力衰竭治疗研究已经显示出在选择心力衰竭患者中的一些益处。对新疗法的进一步研究将有助于改善心力衰竭患者的预后。
